Base de dados : LILACS
Pesquisa : D01.220 [Categoria DeCS]
Referências encontradas : 2 [refinar]
Mostrando: 1 .. 2   no formato [Detalhado]

página 1 de 1

  1 / 2 LILACS  
              next record last record
para imprimir
Texto completo SciELO Brasil
Texto completo
Id: lil-592178
Autor: Sarquis, Otília; Oliveira, Lívia S; Rego, Reginaldo; Gonçalves, Jaylei M; Lima, Marli M; Maciel-de-Freitas, Rafael.
Título: Evaluation of RbCl and CrCl3 as markers of Triatoma brasiliensis (Hemiptera: Reduviidae) nymphs: persistence and influence of Rb and Cr on triatomine biology
Fonte: Mem. Inst. Oswaldo Cruz;106(4):385-389, June 2011. mapas, tab.
Idioma: en.
Resumo: In order to mark Triatoma brasiliensis, the vector of Chagas disease in Brazil, two chemical compounds, rubidium chloride (RbCl) and chromium chloride (CrCl3), were tested. First, 199 N2-N5 nymphs were fed on blood with 0.025M RbCl. Rb marker positivity ranged from 2.5 percent (N3)-70 percent (N2), with a maximum persistence of 98 days. Second, 265 N2-N5 nymphs were fed on blood containing 0.0015M CrCl3. Cr marker positivity ranged up to 93 percent (N5), with a maximum persistence of 119 days. Finally, we blood fed 213 T. brasiliensis to investigate whether CrCl3 altered the biology of this insect. The developmental time of T. brasiliensis was unaltered, but the survival of the Cr-marked group was lower than that of the control group. Differences in the mean fecundity of the control (mean of 156.1) and experimental (mean of 135.6) groups were not statistically significant and 100 percent of the egg batches of females Cr-marked as nymphs were positive. In conclusion, CrCl3 is a useful tool for marking T. brasiliensis nymphs due to its high positivity and persistence.
Descritores: Cloretos/farmacocinética
Compostos de Cromo/farmacocinética
Insetos Vetores/fisiologia
-Doença de Chagas/transmissão
Insetos Vetores
Fatores de Tempo
Limites: Animais
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME

  2 / 2 LILACS  
              first record previous record
para imprimir
Id: lil-172315
Autor: Zubillaga, M. B; Boccio, J. R; Nicolini, J. O; Ughetti, R; Lanari, E; Caro, R. A.
Título: Great particles (32P) chromic phosphate for treatment of solid tumors
Fonte: Acta physiol. pharmacol. ther. latinoam;46(2):103-10, 1996. tab, graf.
Idioma: en.
Projeto: University of Buenos Aires; . CONICET.
Resumo: With the purpose studying the effectivity of an intratumoral single dose of chromic [(32)P] phosphate with great particles for the treatment of solid tumors, studies of biolimination, biodistribution and therapeutic action were carried out. Only for comparative purpose, similar studies were undertaken using a solution of sodium [(32)P] orthophosphategelatine. The results show that when sodium [(32)P] orthophosphategelatine is used, the percentage of total elimination is (85.90+8,70) per cent with a higler percentage in urine (64.50+13.70) per cent than in faeces (21.40+4.50) per cent. In biodistribution studies, the greater percentage is found in bone (15.54+2.21) per cent while only a (2.51+0.39) per cent remains in the tumor. When great particles chromic [(32)P] phosphate was intratumorally injected, we determined that the total elimination is equal (36.28+6.27) per cent, finding a higler amount in faeces (29.44+5.26) per cent than in urine (6.84+2.21) per cent. Biodistribution studies demonstrated that (49.82+5.41) per cent remains in the tumor and (9.63+4.89) per cent of the injected activity is found in the liver. On the other hand, when therapeutic action was evoluted, we observed that the percentage of tumor regression (P.T.R) is 52.0 per cent for the tumors injected with chromic [(32)P] phosphate and 0.0 per cent for those injected with sodium [(32)P] orthophosphate-gelatine. These results show that the great particles colloid of chromic [(32)P] phosphate is not safe enough for the tratment of solid tumors, since it is mobilezed from the injection point, delivering a high dose to the whole organism.
Descritores: Adenocarcinoma/radioterapia
Compostos de Cromo/uso terapêutico
Neoplasias Mamárias Experimentais/radioterapia
Fosfatos/uso terapêutico
Radioisótopos de Fósforo/uso terapêutico
Sódio/uso terapêutico
-Compostos de Cromo/administração & dosagem
Compostos de Cromo/farmacocinética
Fosfatos/administração & dosagem
Radioisótopos de Fósforo/administração & dosagem
Radioisótopos de Fósforo/farmacocinética
Ratos Sprague-Dawley
Indução de Remissão
Sódio/administração & dosagem
Resultado do Tratamento
Limites: Animais
Tipo de Publ: Estudo Comparativo
Responsável: BR1.1 - BIREME

página 1 de 1

Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde